Business NewsPR NewsWire • BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data

BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data

BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data

LUND, Sweden, Jan. 11, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement with Cancer Research UK (CRUK), the world's leading cancer charity, for its unique anti-FcγRIIB antibody,...

View More : https://www.prnewswire.com:443/news-releases/bioinvent-streamlines-agreement-on-anti-fcrllb-antibody-bi-1206-ahead-of-ph...
Releted News by prnewswire
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating CBAK Energy Technology (CBAT) for Possible Securities Fraud, Encourages CBAT Investors and Persons Who May be Able to Assist to Contact its Attorneys Now
BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data
Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference
Zoomd startet seine intelligente Self-Serve SaaS-Plattform zur Verwaltung von Werbekampagnen